Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLA1 | P09884 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.42 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.42 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.42 |
| ▸ | P2RY2 | P41231 | 7/20 | 0.42 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.42 |
| ▸ | P2RY6 | Q15077 | 4/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20427395 | 0.91 | SLC29A1 (0.41) | POLA1CYP3A4CYP2C9SLC28A1SLC28A2 | |
| SCHEMBL800372 | 0.91 | SLC29A1 (0.41) | POLA1CYP3A4CYP2C9SLC28A1SLC28A2 | |
| SCHEMBL13134626 | 0.91 | SLC29A1 (0.41) | POLA1CYP3A4CYP2C9SLC28A1SLC28A2 | |
| SCHEMBL805145 | 0.83 | CYP3A4 (0.45) | POLA1CYP3A4CYP2C9SLC28A1SLC28A2 | |
| SCHEMBL800274 | 0.82 | POLA1 (0.38) | POLA1CYP3A4CYP2C9SLC28A1SLC28A2 | |
| SCHEMBL26268767 | 0.82 | POLA1 (0.48) | POLA1CYP3A4CYP2C9SLC28A1SLC28A2 | |
| SCHEMBL12827120 | 0.82 | POLA1 (0.44) | POLA1SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL540156 | 0.80 | P2RY2 (0.41) | POLA1CYP3A4CYP2C9SLC28A1SLC28A2 | |
| SCHEMBL10492407 | 0.80 | P2RY2 (0.41) | POLA1CYP3A4CYP2C9SLC28A1SLC28A2 | |
| SCHEMBL541102 | 0.80 | P2RY2 (0.41) | POLA1CYP3A4CYP2C9SLC28A1SLC28A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | ALIOS BIOPHARMA, INC. (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120070411-A1 | SUBSTITUTED NUCLEOTIDE ANALOGS | PNP, NTPCR, NUDT1 | POLA1 232/4885CYP3A4 3278/4885CYP2C9 3385/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.